A practical reference on lyophilized powder: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-05-23 and is reviewed periodically as new material appears.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | Built on a 29 residue sequence |
| Primary target | GHRH receptor (GHRHR) | Class B G protein coupled receptor |
| Unconjugated half life | Minutes | Limited by protease degradation |
| Key modification | Four residue substitutions | Positions 2, 8, 15 and 27 |
| Common synonym | Modified GRF(1-29) | Usually denotes the form without DAC |
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
2-Nonenal is an unsaturated aldehyde. The colorless liquid is an important aroma component of aged beer and buckwheat, and is insoluble in water. 2-Nonenal reacts with the Wittig reagent methylenetriphenylphosphorane to give hexyl-1,3-butadiene.
With the help of Charles Stearn, an expert on vacuum pumps, in 1878, Swan developed a method of processing that avoided the early bulb blackening. This received a British Patent in 1880. On 18 December 1878, a lamp using a slender carbon rod was demonstrated at a meeting of the Newcastle Chemical Society though it only worked for a few minutes. Swan repeated the demonstration at another meeting on 17 January 1879 where it worked successfully. It was shown to 700 who attended a meeting of the Literary and Philosophical Society of Newcastle upon Tyne on 3 February 1879. The society's building was the first public building to be lit by electricity. The lamps Swan demonstrated used a carbon rod from an arc lamp rather than a slender filament. Thus they had low resistance and required very large conductors to supply the necessary current, so they were not commercially practical, although they furnished a demonstration of the possibilities of incandescent lighting with relatively high vacuum, a carbon conductor, and platinum lead-in wires. This bulb lasted about 40 hours. Swan then turned his attention to producing a better carbon filament and the means of attaching its ends. He devised a method of treating cotton to produce 'parchmentised thread' in the early 1880s and obtained British Patent 4933 that same year. From this year he began installing light bulbs in homes and landmarks in England. His house, Underhill, Low Fell, Gateshead, was the first in the world to be lit by a lightbulb. In the early 1880s he had started his company.
==== Llansó National Masonic Asylum ==== In 2023, rumors started circulating on social media that the Hogar Nacional Masónico Llansó (English: Llansó National Masonic Retirement Home), a retirement home specifically for elderly Cuban Freemasons, had 21,000 dollars of cash (unspecified "freely convertible" currency) in their treasury. After these social media posts started circulating, the Board of Trustees worried they might be robbed, because Llansó is located in a "rough part of town," in Arroyo Naranjo near La Güinera neighborhood of Havana. Grand Master Mario Urquía Carreño, who also served as the Co-President of the Board of Trustees for Llansó, volunteered that his own office safe could store the money. 19,000 of the cash was then transferred to the vaults of the Grand Lodge of Cuba at the National Masonic Temple, the rest of this money the retirement home kept for expenses and emergencies. The money transfer was signed by three Worshipful Brothers present for the transaction. The Grand Master's office was on the eleventh floor, the top floor, of the National Masonic Temple. At a Board of Trustees meeting in October 2023, Ángel Santiesteban Prats, representing the office of Grand Commander Viñas Alonso, requested a monthly count of the money be performed by Grand Treasurer Airán Cervera. Grand Master Urquía Carreño informed Santiesteban Prats that the money was in the vault of his own office, not in the possession of the Grand Treasurer.
A 2013 meta-analysis by the Cochrane Collaboration compared the effectiveness of non-removable pressure relieving interventions, such as casts, with therapeutic shoes, dressings, removable pressure relieving orthotic devices, and surgical interventions. Non-removable pressure-relieving interventions, including non-removable casts with an Achilles tendon lengthening component, were found to be more effective at healing foot ulcers related to diabetes than therapeutic shoes and other pressure-relieving approaches. TCC systems include TCC-EZ (Integra LifeSciences) and Cutimed Off-loader (BSN Medical).
Cannabis has an ancient history of ritual use and has been used by religions around the world. It has been used as a drug for both recreational and entheogenic purposes and in various traditional medicines for centuries. The earliest evidence of cannabis smoking has been found in the 2,500-year-old tombs of Jirzankal Cemetery in the Pamir Mountains in Western China, where cannabis residue were found in burners with charred pebbles possibly used during funeral rituals. Hemp seeds discovered by archaeologists at Pazyryk suggest early ceremonial practices like eating by the Scythians occurred during the 5th to 2nd century BC, confirming previous historical reports by Herodotus. It was used by Muslims in various Sufi orders as early as the Mamluk period, for example by the Qalandars. Smoking pipes uncovered in Ethiopia and carbon-dated to around c. AD 1320 were found to have traces of cannabis.
Sources: en.wikipedia.org
=== Editorial === Bhatt was Senior Associate Editor for News and Clinical Trials for ACC.org, member of the Healio | Cardiology Today Editorial Board, and Editor-in-Chief of the Journal of Invasive Cardiology, which also lists him as:
The choice of starting material is key to the design of a purification process. In a plant or animal, a particular protein usually is not distributed homogeneously throughout the body; different organs or tissues have higher or lower concentrations of the protein. The use of only the tissues or organs with the highest concentration decreases the volumes needed to produce a given amount of purified protein. If the protein is present in low abundance, or if it has a high value, scientists may use recombinant DNA technology to develop cells that will produce large quantities of the desired protein (this is known as an expression system). Recombinant expression allows the protein to be tagged, e.g. by a His-tag or Strep-tag to facilitate purification, reducing the number of purification steps required. Analytical purification generally utilizes three properties to separate proteins. First, proteins may be purified according to their isoelectric points by running them through a pH-graded gel or an ion exchange column. Second, proteins can be separated according to their size or molecular weight via size exclusion chromatography or by SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) analysis. Proteins are often purified by using 2D-PAGE and are then analysed by peptide mass fingerprinting to establish the protein identity. This is very useful for scientific purposes and the detection limits for protein are nowadays very low and nanogram amounts of protein are sufficient for their analysis.
== A == ABO blood group system – abscisic acid – absorption spectrum – abyssal zone – acetylcholine – acetyl-CoA – acid – acid precipitation – acoelomate – acrosome – actin – action potential – active site – adaptive radiation – address-message concept – adenosine 5'-triphosphate – adenylyl cyclase – adrenal gland – adrenodoxin – aerobic organism – age structure – agonist – AIDS – albumin – aldehydes – aldosterone – algae – allantois – allele – allometry – allopatric speciation – allosteric binding site – allosteric effector – allosteric enzyme – allosteric site – allozyme – alpha helix – amino acid – aminoacyl tRNA synthetase – amino group – amniocentesis – amniote – amphipathic molecule – anabolism – anaerobic organism – anaerobic respiration – androgen – anemia – aneuploidy – angiosperm – anther – anthrax – antibiotic – antibody – anticodon – antidiuretic hormone – antigen – apical dominance – apical meristem – apolipoprotein – apoplast – apoptosis – aquaporin – Archaea – archegonium – arteriosclerosis – artery – arthritis – ascus – asexual reproduction – atomic number – ATP – ATP synthase – atrioventricular valve – atrium – autoimmune disease – autonomic nervous system – autosome – auxin – axillary bud – axon
== Use and effects == According to Alexander Shulgin in his book TiHKAL (Tryptamines I Have Known and Loved), 6-HO-DET has been reported to be active at a dose of 10 mg by intramuscular injection. Lower doses of 1 to 2 mg were inactive, whereas 5 mg produced threshold effects. The drug at a dose of 10 mg was said to produce psychedelic effects very similar to those with 60 mg diethyltryptamine (DET), with these effects starting after 1 hour and lasting 2 to 3 hours. Based on this report, the drug would be about 5 to 6 times more potent than DET in humans. However, this report of 6-HO-DET's properties and effects is a second-hand early account in a single subject provided by Stephen Szara and colleagues and has not been replicated. Moreover, it is seemingly inconsistent with the inactivity of the closely related compounds 6-HO-DMT, 6-MeO-DMT, and 6-fluoro-DET. Relatedly, Shulgin wrote in TiHKAL that it is generally accepted that 6-HO-DET is inactive.
Sources: en.wikipedia.org
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.
DAC stands for drug affinity complex, a term describing the maleimidopropionic acid linker. This group forms a covalent bond with the cysteine residue on serum albumin after administration. The resulting adduct is what extends the circulating half life from minutes to days.
No. It is entirely synthetic and does not correspond to any known endogenous peptide. The design starts from human growth hormone releasing hormone and introduces deliberate substitutions. Any biological effect comes from mimicking the natural hormone at its receptor.
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.